- Stocks
- Pharma & Healthcare
- Medico Remedies
Medico Remedies share price
NSE: MEDICOPharma & HealthcareDrug Manufacturers - Specialty & Generic
Medico Remedies at a glance
Medico Remedies (NSE: MEDICO) closed at ₹20.71 on 22 Oct 2026, down 0.43% on the day. With a market capitalisation of ₹172 Cr, it ranks 2357th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 13.1× trailing earnings, against a return on equity of 17.4% in FY26. Over the past year the share price has fallen 57.5%. Its 52-week range is ₹20.47 (29 Sep 2026) to ₹56.88 (24 Dec 2025); the last close is 63.6% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹27,369 Cr (+84.8% year on year) and net profit ₹1,017 Cr, on a consolidated basis. Promoters held 61.38% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹172 CrRank 2357 on NSE
- P/E (trailing)
- 13.1×
- Price to book
- 3.59×FY26
- EPS (TTM)
- ₹280.30to Q1 FY27
- ROE
- 17.4%FY26
- ROCE
- 26.2%FY26
- Debt to equity
- 0.25FY26
- Net profit margin
- 6.4%FY26
- Book value / share
- ₹9.10FY26
- 52-week high
- ₹56.8824 Dec 2025
- 52-week low
- ₹20.4729 Sep 2026
- 1-year return
- −57.5%
- RSI (14-day)
- 23.1
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.43% | −6.3% | −39.3% | −46.1% | −57.5% |
Medico Remedies quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹12,086 Cr | ₹12,925 Cr | ₹17,249 Cr | ₹14,812 Cr | ₹16,327 Cr | ₹15,683 Cr | ₹16,817 Cr | ₹27,369 Cr |
| Revenue YoY | −26.9% | −25.6% | −2.7% | −13.4% | +35.1% | +21.3% | −2.5% | +84.8% |
| Net profit | −₹648 Cr | ₹10 Cr | ₹450 Cr | −₹57 Cr | ₹702 Cr | ₹987 Cr | ₹1,400 Cr | ₹1,017 Cr |
| Net profit YoY | −154.5% | −97.1% | −26.5% | −116.5% | — | +9,338.0% | +211.1% | — |
| Net margin | −5.4% | 0.1% | 2.6% | −0.4% | 4.3% | 6.3% | 8.3% | 3.7% |
| EPS | −₹42.56 | ₹1.40 | ₹31.56 | −₹2.69 | ₹48.30 | ₹67.26 | ₹95.48 | ₹69.26 |
Medico Remedies financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹122 Cr | ₹121 Cr | ₹140 Cr | ₹145 Cr | ₹151 Cr | — |
| Operating profit | ₹4 Cr | ₹7 Cr | ₹10 Cr | ₹11 Cr | ₹14 Cr | — |
| Net profit | ₹3 Cr | ₹5 Cr | ₹7 Cr | ₹8 Cr | ₹10 Cr | — |
| EPS (₹) | ₹6.25 | ₹2.95 | ₹0.87 | ₹1.00 | ₹1.22 | — |
| Cash from operations | ₹3 Cr | ₹2 Cr | ₹8 Cr | ₹0 Cr | ₹5 Cr | — |
| Total debt | ₹5 Cr | ₹1 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹32 Cr | ₹37 Cr | ₹44 Cr | ₹52 Cr | ₹62 Cr | ₹75 Cr |
Medico Remedies shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 63.79% | 62.59% | 61.38% | 61.38% | 61.38% | 61.38% |
| Foreign institutions | 0.12% | 0.07% | 0.30% | 0.49% | 0.03% | 0.08% |
| Non-institutions | 36.08% | 37.33% | 38.30% | 38.13% | 38.59% | 38.54% |
Medico Remedies vs peers
The listed Pharma & Healthcare companies nearest to Medico Remedies by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| ANLAccretion Nutra | — | — | — | ₹184 Cr | — | — |
| EARKARTEarkart | — | — | — | ₹182 Cr | — | — |
| NOVELIXNovelix Pharma | — | — | — | ₹181 Cr | — | — |
| BALPHARMABal Pharma | ₹109.58 | −2.16% | +28.9% | ₹174 Cr | 27.7 | — |
| MEDICOMedico Remedies | ₹20.71 | −0.43% | −57.5% | ₹172 Cr | 13.1 | — |
| MADHAVBAUGVaidya Sane Ayu | ₹161.10 | −4.11% | −43.1% | ₹169 Cr | — | — |
| TAKETake Solutions | ₹11.23 | −1.23% | −36.8% | ₹166 Cr | 38.7 | — |
Ask anything about Medico Remedies
Pivot answers on the live chart with evidence you can check, and tests strategies against MEDICO's own history. Try: “Why has MEDICO moved over the last three months?” · “Backtest a 50-day moving-average crossover on MEDICO over five years” · “Compare MEDICO with ANL on margins and valuation”
Frequently asked questions about Medico Remedies
What is the share price of Medico Remedies today?
Medico Remedies (NSE: MEDICO) last closed at ₹20.71 on 22 Oct 2026. Its 52-week high is ₹56.88 and its 52-week low is ₹20.47.
What is the market cap of Medico Remedies?
Medico Remedies' market capitalisation is ₹172 Cr (₹172 Cr) at the 22 Oct 2026 close, ranking 2357th among the NSE companies Pivot tracks.
What is the P/E ratio of Medico Remedies?
Medico Remedies trades at a trailing P/E of 13.1.
What is the ROE and ROCE of Medico Remedies?
Return on equity was 17.4% in FY26 and return on capital employed was 26.2% in FY26 (standalone figures).
Is Medico Remedies a debt-free company?
No. Medico Remedies' debt-to-equity ratio was 0.25 in FY26, with total debt of ₹0 Cr.
What were Medico Remedies' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Medico Remedies reported revenue of ₹27,369 Cr, +84.8% year on year, and net profit of ₹1,017 Cr.
How has Medico Remedies stock performed over the last year?
Medico Remedies' share price has fallen 57.5% over the past year, −46.1% over three months and −39.3% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Medico Remedies?
As of 30 Jun 2026: promoters 61.38%, foreign institutions 0.08%, non-institutions 38.54%.
Who are Medico Remedies' competitors?
The listed Pharma & Healthcare companies closest to Medico Remedies by market cap are Accretion Nutra, Earkart, Novelix Pharma, Bal Pharma, Vaidya Sane Ayu and Take Solutions.
Is Medico Remedies a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Medico Remedies' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on MEDICO against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with M · all NSE stocks · this page as text